Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FLU/SAL inhalers for COPD carry greater pneumonia risk

Publish date:: June 4, 2020

Key clinical point: Study supports evidence that selected corticosteroid inhalers lower pneumonia risk in COPD patients.

Major finding: Budesonide/formoterol users had a 17% lower risk of severe pneumonia than that of fluticasone propionate/salmeterol users.

Study details: Retrospective cohort study of 42,393 COPD patients new to ICS/LABA from 2011 to 2015 using national claims data from in Taiwan.

Disclosures: The Taiwan Ministry of Science and Technology provided partial support for the study. Ting-Yu Chang, MS, and colleagues have no relationships to disclose.

Citation:

Chang TY et al. CHEST. 2020;157:117-29.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Infectious Diseases

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Vaccine-preventable infection risk high for pediatric hematopoietic cell transplantation recipients,

Three genes could predict congenital Zika infection susceptibility,

Obesity, hypoxia predict severity in children with COVID-19,

Two consecutive negative FUBC results clear S. aureus bacteremia,